FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064021099> ?p ?o ?g. }

• W2064021099 endingPage "419" @default.
• W2064021099 startingPage "413" @default.
• W2064021099 abstract "Epidermal growth factor receptor gene (EGFR) alteration is a common feature in most of glioblastoma multiforme (GBM). Robust response of anti-EGFR treatments has been mostly associated with the EGFR deletion mutant variant III (EGFRvIII) and expression of PTEN. We have performed a prospective trial in order to confirm the efficacy of erlotinib treatment in patients with relapsed GBM who expressed EGFRvIII and PTEN. All patients included in the trial were required to be PTEN (+++), EGFR (+++) and EGFRvIII (+++) positives by immunohistochemistry. This new phase II trial enrolled 40 patients and was design to be stopped in case of fewer than two responses in the first 13 patients. Patient eligibility included histopathology criteria, radiological progression, more than 18 years old, Karnofsky performed status, KPS > 50, and adequate bone marrow and organ function. There was no limit to the number of prior treatments for relapses. No enzyme-inducing antiepileptic drugs were allowed. The primary endpoints were response and progression-free survival at 6 months (PFS6). Thirteen patients (6 men, 7 women) with recurrent GBM received erlotinib 150 mg/day. Median age was 53 years, median KPS was 80, and median prior treatments for relapses were 2. There was one partial response and three stable diseases (one at 18 months). PFS at 6 months was 20 %. Dose reduction for toxicity was not needed in any patient. Dermatitis was the main treatment-related toxicity, grade 1 in 8 patients and grade 2 in 5 patients. No grade 3 toxicity was observed. Median survival was 7 months (95 % IC 1.41–4.7). As conclusion, monotherapy with erlotinib in GBM relapses patients with high protein expression for PTEN (+++), EGFR (+++), and EGFRvlII (+++) showed low toxicity but minimal efficacy and the trial stopped." @default.
• W2064021099 created "2016-06-24" @default.
• W2064021099 creator A5009894963 @default.
• W2064021099 creator A5019753819 @default.
• W2064021099 creator A5027875773 @default.
• W2064021099 creator A5045357207 @default.
• W2064021099 creator A5052018961 @default.
• W2064021099 creator A5052749916 @default.
• W2064021099 creator A5054100322 @default.
• W2064021099 creator A5054498659 @default.
• W2064021099 creator A5055002084 @default.
• W2064021099 creator A5068271097 @default.
• W2064021099 creator A5069385617 @default.
• W2064021099 creator A5082835290 @default.
• W2064021099 creator A5083684125 @default.
• W2064021099 date "2013-12-19" @default.
• W2064021099 modified "2023-10-15" @default.
• W2064021099 title "Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry" @default.
• W2064021099 cites W1963558982 @default.
• W2064021099 cites W1978916359 @default.
• W2064021099 cites W1996454752 @default.
• W2064021099 cites W2054455334 @default.
• W2064021099 cites W2057919501 @default.
• W2064021099 cites W2067635558 @default.
• W2064021099 cites W2070705072 @default.
• W2064021099 cites W2082148749 @default.
• W2064021099 cites W2086216067 @default.
• W2064021099 cites W2104743043 @default.
• W2064021099 cites W2109816625 @default.
• W2064021099 cites W2117941094 @default.
• W2064021099 cites W2121889629 @default.
• W2064021099 cites W2135836172 @default.
• W2064021099 cites W2139473501 @default.
• W2064021099 cites W2148141962 @default.
• W2064021099 cites W2150575159 @default.
• W2064021099 cites W2158106887 @default.
• W2064021099 cites W2160137787 @default.
• W2064021099 cites W2168796485 @default.
• W2064021099 cites W2943197679 @default.
• W2064021099 doi "https://doi.org/10.1007/s11060-013-1316-y" @default.
• W2064021099 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4713960" @default.
• W2064021099 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24352766" @default.
• W2064021099 hasPublicationYear "2013" @default.
• W2064021099 type Work @default.
• W2064021099 sameAs 2064021099 @default.
• W2064021099 citedByCount "31" @default.
• W2064021099 countsByYear W20640210992014 @default.
• W2064021099 countsByYear W20640210992015 @default.
• W2064021099 countsByYear W20640210992016 @default.
• W2064021099 countsByYear W20640210992017 @default.
• W2064021099 countsByYear W20640210992018 @default.
• W2064021099 countsByYear W20640210992019 @default.
• W2064021099 countsByYear W20640210992020 @default.
• W2064021099 countsByYear W20640210992021 @default.
• W2064021099 countsByYear W20640210992022 @default.
• W2064021099 countsByYear W20640210992023 @default.
• W2064021099 crossrefType "journal-article" @default.
• W2064021099 hasAuthorship W2064021099A5009894963 @default.
• W2064021099 hasAuthorship W2064021099A5019753819 @default.
• W2064021099 hasAuthorship W2064021099A5027875773 @default.
• W2064021099 hasAuthorship W2064021099A5045357207 @default.
• W2064021099 hasAuthorship W2064021099A5052018961 @default.
• W2064021099 hasAuthorship W2064021099A5052749916 @default.
• W2064021099 hasAuthorship W2064021099A5054100322 @default.
• W2064021099 hasAuthorship W2064021099A5054498659 @default.
• W2064021099 hasAuthorship W2064021099A5055002084 @default.
• W2064021099 hasAuthorship W2064021099A5068271097 @default.
• W2064021099 hasAuthorship W2064021099A5069385617 @default.
• W2064021099 hasAuthorship W2064021099A5082835290 @default.
• W2064021099 hasAuthorship W2064021099A5083684125 @default.
• W2064021099 hasBestOaLocation W20640210991 @default.
• W2064021099 hasConcept C121608353 @default.
• W2064021099 hasConcept C126322002 @default.
• W2064021099 hasConcept C143998085 @default.
• W2064021099 hasConcept C190283241 @default.
• W2064021099 hasConcept C204232928 @default.
• W2064021099 hasConcept C2777609662 @default.
• W2064021099 hasConcept C2778087573 @default.
• W2064021099 hasConcept C2779438470 @default.
• W2064021099 hasConcept C29730261 @default.
• W2064021099 hasConcept C55493867 @default.
• W2064021099 hasConcept C71924100 @default.
• W2064021099 hasConcept C86554907 @default.
• W2064021099 hasConcept C86803240 @default.
• W2064021099 hasConcept C90924648 @default.
• W2064021099 hasConceptScore W2064021099C121608353 @default.
• W2064021099 hasConceptScore W2064021099C126322002 @default.
• W2064021099 hasConceptScore W2064021099C143998085 @default.
• W2064021099 hasConceptScore W2064021099C190283241 @default.
• W2064021099 hasConceptScore W2064021099C204232928 @default.
• W2064021099 hasConceptScore W2064021099C2777609662 @default.
• W2064021099 hasConceptScore W2064021099C2778087573 @default.
• W2064021099 hasConceptScore W2064021099C2779438470 @default.
• W2064021099 hasConceptScore W2064021099C29730261 @default.
• W2064021099 hasConceptScore W2064021099C55493867 @default.
• W2064021099 hasConceptScore W2064021099C71924100 @default.
• W2064021099 hasConceptScore W2064021099C86554907 @default.
• W2064021099 hasConceptScore W2064021099C86803240 @default.

• next